Author: Benzinga Newsdesk | August 14, 2025 03:42pm
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.12 percent. This is a 74.65 percent increase over losses of $(2.17) per share from the same period last year.